Cagnoni Pablo J
SEC-identified person · CIK 1205703 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Incyte Corp INCY | President, R&D | filed 2023–2026 |
| Fusion Pharmaceuticals Inc. FUSN | Director | filed 2020–2024 |
| Rubius Therapeutics, Inc. RUBY | Director · Chief Executive Officer | filed 2018–2023 |
| Turmeric Acquisition Corp. TMPM | Director | filed 2020–2020 |
| Crispr Therapeutics AG CRSP | Director | filed 2016–2019 |
| Onyx Pharmaceuticals INC ONXX | EVP, Global R&D and Tech Ops | filed 2013–2013 |
| Allos Therapeutics INC ALTH | Sr. VP, Chief Medical Officer | filed 2007–2009 |
| OSI Pharmaceuticals INC OSIP | VP & Chief Medical Officer | filed 2006–2006 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.